The US Food and Drug Administration has approved Radiesse for the treatment of décolleté wrinkles, extending the injectable's on-label reach beyond its existing facial and hand indications.

The Dermatology Digest reported the clearance under its Regenerative Aesthetics banner, framing the move as part of a broader trade-press effort to categorise biostimulatory and collagen-induction procedures as a distinct clinical category. For medical-aesthetic practices, the approval reframes what had been an off-label workflow into a documented, manufacturer-supported protocol.

What does the new indication actually cover?

The clearance covers moderate to severe décolleté wrinkles, a presentation most clinicians associate with chronic UV exposure, sleep-position creasing and age-related dermal thinning. Practitioners have long treated the chest area with off-label hyaluronic acid fillers, biostimulators and energy-based devices, but explicit FDA language on a calcium hydroxylapatite (CaHA) product for this anatomical site had been absent until now.

With the new label, clinicians can schedule décolleté sessions under the same medico-legal posture they already use for cheek and hand augmentation. That shift has practical knock-on effects across the practice:

• Patient consent templates can reference an FDA-cleared indication rather than off-label use
• Documentation for insurance, coding and reimbursement conversations becomes simpler
• Patient-facing marketing no longer needs to carry off-label disclaimers
• Inventory planning can allocate CaHA stock across a fuller service menu

What does this change for compliance and procurement?

For compliance officers at clinics and medspas, the expansion triggers a paperwork refresh. Consent forms, photography protocols, post-market tracking logs and adverse-event reporting templates should be updated to capture the new indication, and staff training records should reflect credentials for chest-area injection.

Procurement teams will see less immediate disruption. Radiesse is typically sold in standard syringe volumes, so SKU counts rarely change with an indication expansion. What changes is allocation: practices that previously reserved CaHA for facial volume loss may now plan dedicated chest-area appointments and reorder accordingly.

How does the regenerative-aesthetics framing affect positioning?

The Regenerative Aesthetics label used by The Dermatology Digest is not incidental. CaHA fillers sit in that category because their microsphere scaffold prompts neocollagenesis rather than acting purely as a passive volumiser. Clinics that have already built a regenerative menu — pairing injectables with microneedling, radiofrequency, polynucleotides or exosome adjuvants — can now anchor the décolleté protocol to a labeled biostimulator.

For competitors in the broader biostimulator space, the approval raises the bar for label-supported body-area claims. Practices and formulators tracking the segment should expect competing manufacturers to accelerate their own chest-area study programs in response.

What should clinicians and formulators watch next?

Three downstream signals will define how quickly this clearance translates into routine practice. First, the updated package insert will specify eligible patient profiles, injection depth, recommended volumes and any post-injection massage protocols specific to the chest. Second, manufacturer cadaver-lab and trainer programs typically roll out within weeks of an FDA action, and those sessions will determine how rapidly clinics credential staff. Third, the peer-reviewed publication of the pivotal trial will give compliance and marketing teams the clinical numbers behind the new claim.

Practices that have been informally offering chest-area Radiesse off-label should audit their pre-approval charts now. Treatment counts, baseline photography and adverse-event logs from the off-label era will become useful benchmarks once the on-label patient population begins to accumulate — and regulators increasingly ask for that historical record when post-market data comes up for review.